U.S. Markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.12+0.03 (+0.49%)
At close: 4:00PM EDT
People also watch
NVAXHEBVICLARRYAGEN

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919-859-1302
http://www.biocryst.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedAge
Mr. Jon P. StonehouseChief Exec. Officer, Pres and Exec. Director533.98k81.93k56
Mr. Thomas R. Staab II, CPAChief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer436.67k89.58k49
Dr. William P. Sheridan MBBSChief Medical Officer and Sr. VP494.11kN/A62
Dr. Yarlagadda S. Babu Ph.D.Sr. VP of Drug Discovery386.4kN/A64
Ms. Lynne M. PowellChief Commercial Officer and Sr. VP390.14kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate Governance

BioCryst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.